Company Announcement no. 5/2011


To: NASDAQ OMX Copenhagen A/S
Hørsholm, Denmark, April 12, 2011



LIFECYCLE PHARMA A/S PASSING OF ANNUAL GENERAL MEETING -
APPOINTMENT OF KIM BJØRNSTRUP AS CHAIRMAN OF BOARD OF DIRECTORS.



Summary: At LifeCycle Pharma A/S' Annual General Meeting held earlier today,
the Annual Report was approved. All proposals from the Board of Directors were
adopted.


At the general meeting, the report by the Board of Directors and Management was
adopted and the audited Annual Report was approved.


It was decided that the year's net loss of DKK 274.2 million be carried forward
by transfer to accumulated deficit. The fee to the Board of Directors for 2010
was approved as a separate item on the agenda.


All existing members of the Board of Directors standing for re-election were
re-elected. In addition, Kim Bjørnstrup was elected as a new Board Member. All
were elected for a period of one year that expires at the Annual General
Meeting to be held in 2012.


The Board of Directors constituted itself with Kim Bjørnstrup as Chairman of
the Board of Directors and as Chairman of the Compensation Committee, Thomas
Dyrberg as Deputy Chairman of the Board of Directors, and Kurt Anker Nielsen as
Chairman of the Audit Committee.


The Board of Directors will hereafter comprise:


-- Kim Bjørnstrup (Chairman)
-- Thomas Dyrberg (Deputy Chairman)
-- Kurt Anker Nielsen
-- Anders Götzsche
-- Mette Kirstine Agger

PricewaterhouseCoopers, Statsautoriseret Revisionsaktieselskab, was re-elected
as the Company's auditor.


The proposals from the Board of Directors to change Article 11 so that it is no
longer a requirement that convening notices are published in at least 1
national newspaper was approved.


The Board of Directors was authorized by the General Meeting, until the next
Annual General Meeting to arrange for the Company to acquire its own shares up
to a total nominal value of 10% of the Company's nominal share capital. The
purchase price of such shares may not differ by more than 10% from the price
quoted on NASDAQ OMX Copenhagen at the time of the purchase.


The proposals from the Board of Directors that the existing general guidelines
for incentive pay to members of the Board of Directors and the Executive
Management are changed so that the bonus for the Executive Management may
amount to 100 % of the fixed annual cash salary and that the option for board
members to exchange the annual fee for an additional number of warrants be
deleted, was approved.


The chairman of the Annual General Meeting, with right of substitution, was
authorized to register the resolutions passed by the general meeting to the
Danish Commerce and Companies Agency and to make such alterations to as the
Agency may require or request for registration or approval.


LCP's new Chairman Kim Bjørnstrup has more than 20 years of working experience
in the pharmaceutical industry. During the past 18 years, he held various
executive positions in the management team of the Octapharma Group and served
as Vice Chairman until recently. Prior to this he has worked with Coloplast A/S
and H. Lundbeck A/S. Mr. Bjørnstrup is Chairman of the board of Assistance A/S
and a board member of Xeltis AG.


“Mr. Bjørnstrup brings a wealth of experience in the biotech and pharmaceutical
industry and will bring strong leadership to the Board of Directors”, said
Thomas Dyrberg, Deputy Chairman of LCP. “He has significant commercial
experience from his time at Octapharma Group. This experience will be critical
as LCP announces the first phase 3 trial for LCP-Tacro™ this quarter and as we
evolve into a commercial stage company over the next few years. We look forward
to working closely with Kim during this exciting period for the company.”


“LCP has an attractive late stage product in LCP-Tacro™ as well as a very
robust technology platform that has already been validated in several product
candidates and has brought a product to the U.S. market. I am excited to take
on the role of Chairman of the Board of Directors and working to continue to
move LCP forward”, said Mr. Bjørnstrup.


LCP wishes to thank outgoing Chairman Paul Edick and Board Member Gerard Soula
for their services to the company. “We greatly appreciate the contributions of
Paul Edick and Gerard Soula to the growth of LCP. Their inputs have advanced
the Company and provided considerable value to the future growth potential of
LCP,” said Thomas Dyrberg. Mr. Edick and Dr. Soula will be devoting more time
to their CEO activities at their respective companies. Mr. Edick was recently
named CEO of Durata Therapeutics and Dr. Soula is CEO of Adocia.


For more information, please contact:



LifeCycle Pharma A/S Johnny Stilou
John Weinberg, M.D. CFO
SVP, Commercial Operations & Investor Relations Phone: + 45 2055 3817
Phone: +1 732 321 3208 Email: [email protected]
Email: [email protected]

120411 LCP Passing of Annual General Meeting.pdf